anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine for treating premature menstruation, profuse menstruation, breast distending pain and large clot quantity. The traditional Chinese medicine is characterized by consisting of the following components by weight: 10-15 grams of red paeony root, 10-15 grams of white paeony root, 10-15 grams of ramulus et uncus uncariae, 10-15 grams of fried himalayan teasel root, 8-12 grams of fried tree peony bark, 8-12 grams of charred hawthorn, 8-12 grams of trogopterus dung, 8-12 grams of Indian buead, 6-12 grams of fried cape jasmine fruit, 4-8 grams of fried cattail pollen, 12-18 grams of fried Chinese thorowax root and 12-18 grams of motherwort herb. The twelve traditional Chinese medicines are ground into fine powder and filled into capsules or processed into Chinese patent medicaments such as tablets and pills; and the traditional Chinese medicine can be directly decocted with water for taking. The traditional Chinese medicine has a reasonable formula, can be prepared with various preparation methods, has the effects of regulating the menstrual function, relieving pain, arresting bleeding and eliminating blood stasis, and has remarkable curative effects on gynecological diseases such as premature menstruation, profuse menstruation, breast distending pain and large clot quantity. As proved by many years of clinical application, the traditional Chinese medicine has a definite and reliable curative effect and does not have any toxic or side effect. The clinical application effective rate of the traditional Chinese medicine is 95 percent, and the curative ratio is 90 percent.
The invention relates to an anti-PSMP monoclonal antibody 3D5, wherein a heavy chain belongs to an IgG1 subtype, and a light chain belongs to a kappa chain. The invention relates to an anti-PSMP monoclonal antibody 4E7, wherein a heavy chain belongs to an IgG2b subtype, and a light chain belongs to a kappa chain. The 3D5 heavy chain variable region sequences are shown in SEQ ID NO.3 and 5, the heavy chain complementarity determining regions are shown in SEQ ID NO.7,8,9 and 13,14,15, the light chain variable regions are shown in SEQ ID NO.4 and 6, and the light chain complementarity determining regions are shown in SEQ ID NO.10,11,12 and 16,17, 18. 4E7 heavy chain variable region sequences are shown in SEQ ID NO.31 and 33, heavy chain complementarity determining regions are shown in SEQ ID NO.35,36,37 and 41,42,43, light chain variable regions are shown in SEQ ID NO.32 and 34, and light chain complementarity determining regions are shown in SEQ ID NO.38,39,40 and 44,45, 46. The 3D5 and 4E7 anti-PSMP monoclonal antibodies can be used for treating various PSMP-related diseases. The 3D5 and 4E7 anti-PSMP monoclonal antibodies can also be used for detecting the content of PSMP protein in a sample.
DOSAGE MUST BE INDIVIDUALIZED. (See INDICATIONS AND USAGE.) 

Chlorthalidone is usually given at a dose of 25 mg daily; the usual initial dose of atenolol is 50 mg daily. Therefore, the initial dose should be one TENORETIC 50 tablet given once a day. If an optimal response is not achieved, the dosage should be increased to one TENORETIC 100 tablet given once a day. 

When necessary, another antihypertensive agent may be added gradually beginning with 50 percent of the usual recommended starting dose to avoid an excessive fall in blood pressure. 

Since atenolol is excreted via the kidneys, dosage should be adjusted in cases of severe impairment of renal function. No significant accumulation of atenolol occurs until creatinine clearance falls below 35 mL/min/1.73m2 (normal range is 100 mL/min/1.73m2 to 150 mL/min/1.73m2); therefore, the following maximum dosages are recommended for patients with renal impairment.
Patients receive nivolumab IV over 30 minutes on day 1 of each cycle, ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle, and paclitaxel IV over 60 minutes on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI throughout the study. Patients may also optionally undergo blood sample collection on study.
A therapeutic nasal moisturizing formulation for moisturizing the epidermal surface of the nasal cavity and for the prevention of epistaxis. The formulation includes Medium Chain Triglyceride (MCT) coconut oil and tinctures of Achillea millefolium and Pimpinella saxifraga in an approximately 8:1:1 ratio. The MCT oil is preferably fractionated and/or refined to include only caprylic acid, capric acid, and lauric acid. Tinctures can be diluted three times into 1% potency and alcohol may be removed from the tinctures. The formulation may be combined in an approximately 8 to 1 to 1 ratio. A method for the preparation of the formulation and a method of nasal moisturization for the prevention of epistaxis. The method steps include providing the therapeutic formulation and spraying the formulation into the nasal cavity into the nostril(s) of a patient, thereby moisturizing the cavity through the long-lasting moisturization of nasal epidermis and prevention of drying and cracking of nasal epidermis.
Dosage form unit is provided to deliver one or more beneficial agents into a fluid, such as liquid enteral nutritional product. The dosage form unit includes a core containing at least one beneficial agent, preferably a marker dye, which is dispersible in the fluid. The core also contains a compatible binding agent to bind the beneficial agent together. Additional components of the core may include a plasticizer, a standard flow agent, a lubricant, additional tableting aids and at least one hydrophilic agent. A latex coating encases the core. The latex coating includes a mixture containing a substantially hydrophobic base material, preferably formed from an emulsion of cellulose acetate microspheres, which is capable of defining a matrix-type membrane, and at least one hydrophilic component being dispersible in the fluid. A dispersible beneficial agent is preferred as one of the hydrophilic components of the latex coating to allow immediate release of the beneficial agent therefrom. A method of making the dosage form unit also is provided.
Study eyes assigned to receive faricimab will receive a dose of 6.0 mg of faricimab. Faricimab is supplied in a single use vial.
This case report discusses the medical history of a 64-year-old woman diagnosed with scleroderma and diffuse gastrointestinal angiodysplasia. The patient received bevacizumab (BVZ) therapy to address gastrointestinal bleeding that was unresponsive to endoscopic treatment. Subsequently, she developed severe thrombocytopenia. Although there were suspicions of an immune-mediated mechanism resulting from BVZ treatment, the laboratory results did not provide conclusive evidence. The patient underwent transfusions, received gamma globulin, and was treated with Romiplostim. Over time, her platelet levels gradually improved, and the bleeding was successfully controlled. It's worth noting that BVZ-induced thrombocytopenia is a relatively rare yet severe adverse effect. Recognizing and understanding the mechanisms behind thrombocytopenia is essential for developing safer treatment approaches. Further research is required to identify potential risk factors associated with this condition.
There is no state-of-the-art prophylactic treatment for atopy. Once allergy develops, allergens should be avoided, and specific allergen immunotherapy applied. The initial cause of the onset of allergy, namely the immune hyperactive state of the atopic subjects, is not addressed at all. The investigators hypothesize that atopy is defined by a mild functional iron deficiency and that improving the iron status of immune cells will decrease the reactivity of these cells.

In this prophylactic dietary intervention study oral supplementation of placebo or chelated and whey protein-bound iron will be given over the course of six months to allergic and non-allergic women. Changes in 1) the clinical reactivity 2) the iron status and 3) the microflora will be assessed. The study will be the first systematic approach in humans to assess the contribution of iron deficiency to allergy and will be pivotal in supporting the implementation of prophylactic and therapeutic recommendations.
Macrophages are innate immune cells that are known for their extreme plasticity, enabling diverse phenotypes that lie on a continuum. In a simplified model, they switch between pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes depending on surrounding microenvironmental cues, which have been implicated in disease outcomes. Although considerable research has been focused on macrophage response to biochemical cues and mechanical signals, there is a scarcity of knowledge surrounding their behavior in response to shear stress. In this study, we applied varying magnitudes of shear stress on human monocyte-derived macrophages (MDMs) using a cone-and-plate viscometer and evaluated changes in morphology, gene expression, protein expression, and cytokine secretion over time. MDMs exposed to shear stress exhibited a rounder morphology compared to statically-cultured controls. RT-qPCR results showed significant upregulation of TNF-α, and analysis of cytokine release revealed increased secretion of IL-8, IL-18, fractalkine, and other chemokines. The upregulation of pro-inflammatory factors was evident with both increasing magnitudes of shear and time. Taken together, these results indicate that prolonged shear exposure induced a pro-inflammatory phenotype in human MDMs. These findings have implications for medical technology development, such as in situ vascular graft design wherein macrophages are exposed to shear and have been shown to affect graft resorption, and in delineating disease pathophysiology, for example to further illuminate the role of macrophages in atherosclerosis where shear is directly related to disease outcome.
PURPOSE:To provide a new DNA useful for mass production of DSDGK of antiallergic pentapeptide by gene recombinant technique. CONSTITUTION:The DNA containing a base sequence coding the macromer peptide of antiallergic pentapeptide having the amino acid sequence of DSDGK, having e.g. a base sequence of the formula. With a base sequence coding a peptide as recurring unit, single-stranded DNA containing at least two such recurring units is mixed with another single-stranded DNA complementary thereto followed by thermal insulation and cooling to produce such a double- stranded DNA that both the two single-stranded DNAs are mutually complementary and slipped by at least one recurring unit, and dATP, dCTP, dGTP and dTTP are made to react in the presence of DNA polymerase to synthesize the DNA strand complementary to the single-stranded DNA region. The resulting double-stranded DNA is heated and dissociated into a single-stranded DNA and another single-stranded DNA complementary thereto. The operations ranging from the above-mentioned thermal insulation, cooling to the dissociation is repeated at least once, performing the operations of the thermal insulation, cooling and complementary strand synthesis.
PURPOSE: An apparatus for predicting level change of coronary artery calcium (CAC) and a prediction method thereof are provided to increase prevention possibility of heart disease and stroke, by predicting the population group in which degree of danger of the coronary artery calcium is expected to increase in the future. CONSTITUTION: An input part (100) receives medical examination data about coronary artery calcium of a patient and task information about the medical examination data. A cluster designation part (110) designates a belonging cluster to the medical examination data about the coronary artery calcium of the patient on the ground of the characteristics of the patient. An influence variable value extraction part (120) extracts influence variable value used in collecting influence variables of the belonging cluster from the medical examination data. A prediction model learning part (140) performs machine learning, by applying the influence variable value to a prediction model corresponding to the belonging cluster. A prediction part obtains prediction result, by applying the influence variable value to the prediction model. [Reference numerals] (100) Input part; (110) Cluster designation part; (120) Influence variable value extraction part; (130) Prediction model storage unit; (140) Prediction model learning part; (150) Prediction unit; (AA) Medical examination data and job information; (BB) Prediction result
Elderly population is defined as 'people aged 65 or above'. Aging is a complex and challenging process of physiological changes and it is associated with decline of biological functions. Increasing age is linked with impairments in visual, proprioception, vestibular systems, decline in muscular strength and control of the lower limbs, balance/postural control, and of the mobility patterns which are known to be substantial hazards for fall, and these parameters have been found to be dynamically more disabled with getting older. Among all these factors, there is obvious decline in normal functioning and balance related issues, common in elderly population due to proprioceptive function loss that is the person is unable to sense his joint position and motion which ultimately results in mobility impairments.

Therefore, researchers have been looking for new approaches that are more feasible to improve the independence and physical mobility in older individuals and over the past decade the whole body vibrator (WBV) have been seeking attention for the beneficence of the elderly population. It is a neuromuscular training modality used to improve muscle strength, power, balance, mobility, cardiorespiratory rehabilitation, improves neuromuscular and musculoskeletal functions and general health both in healthy and as well as in orthopedic patients and neurologically diseased elderly population .Bilateral proprioceptive training is also used for impaired balance, proprioception loss and decreased ROM in elderly population. Proprioceptive receptors are present in our skin, muscles, tendons and joints with the help of which we can sense position and movement of limbs and trunk, sense of force and sense of heaviness in the absence of vision. The mechanoreceptors of the proprioception cause activation of central nervous system by initiating action potential through release of stored sodium in to the cells, this afferent sensory stimuli to the central nervous system is essential for the control of body movements
Letrazuril, the p-fluor analog of diclazuril, has been shown in an animal model to prevent infections by organisms closely related to the intracellular parasite Cryptosporidium. Reliable data are needed to show the effectiveness of letrazuril in treating AIDS-related cryptosporidial diarrhea.

Four groups of eight patients receive escalating doses of oral letrazuril (or placebo). In each group, six patients are randomized to receive letrazuril and two patients receive matching placebo. In the pharmacokinetics determination phase of the study, patients receive a single dose of letrazuril or placebo following a meal. Following a 72-hour blood collection, patients enter the blinded, treatment phase of the study and receive letrazuril or placebo as a single dose daily, after a meal, for 3 weeks. Patients with persistent Cryptosporidium oocysts in their stools at the end of the blinded treatment phase may continue with open-label treatment of letrazuril at the same dose for 4 weeks; the dose may subsequently be escalated every 4 weeks, to a maximum, if oocysts persist. Patients who have Cryptosporidium oocysts eradicated from their stools will discontinue treatment and be followed for 3 months. All patients undergo clinical follow-up at 3 and 6 months.
An inhibitor of sporeforming pathogens or agents. In one embodiment, the inhibitor has at least one glycoconjugate that is bondable to a sporeforming pathogen or agent. The glycoconjugate is a molecule containing a carbohydrate moiety that is glycosylated. The glycosylated carbohydrate moiety may comprise a glycoprotein or a glycolipid. In one embodiment, the glycosylated carbohydrate moiety comprises at least one disaccharide moiety or higher polysaccharide. In another embodiment, the glycosylated carbohydrate moiety comprises a plurality of copies of same monosaccharide units or different monosaccharide units.
Fatal and life-threatening skin adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have occurred in recipients of POTELIGEO. Rash (drug eruption) is one of the most common adverse reactions associated with POTELIGEO. In Trial 1, 25% (80/319) of patients treated with POTELIGEO had an adverse reaction of drug eruption, with 18% of these cases being severe (Grade 3) and 82% of these cases being Grade 1 or 2. Of 528 patients treated with POTELIGEO in clinical trials, Grade 3 skin adverse reactions were reported in 3.6%, Grade 4 skin adverse reactions in <1%, and SJS in <1%.

The onset of drug eruption is variable, and the affected areas and appearance vary. In Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. The more common presentations reported included papular or maculopapular rash, lichenoid, spongiotic or granulomatous dermatitis, and morbilliform rash. Other presentations included scaly plaques, pustular eruption, folliculitis, non-specific dermatitis, and psoriasiform dermatitis.

Monitor patients for rash throughout the treatment course. Management of dermatologic toxicity includes topical corticosteroids and interruption or permanent cessation of POTELIGEO [see Dosage and Administration (2.2)]. Consider skin biopsy to help distinguish drug eruption from disease progression.

Discontinue POTELIGEO permanently for SJS or TEN or for any life-threatening (Grade 4) reaction. For possible SJS or TEN, interrupt POTELIGEO and do not restart unless SJS or TEN is ruled out and the cutaneous reaction has resolved to Grade 1 or less.
Patients with diabetes mellitus (DM) are at increased risk of atherothrombotic events. Importantly, DM is a key risk factor for the development of chronic kidney disease (CKD), which further enhances atherothrombotic risk. These observations underscore the importance of antiplatelet therapy for prevention of atherothrombotic recurrences in these high-risk patients. Clopidogrel is the most widely used platelet P2Y12 receptor inhibitor. However, despite its clinical benefit, patients with DM and CKD frequently experience recurrent atherothrombotic events. This may be in part due to the impaired pharmacokinetic (PK) and pharmacodynamic (PD) effects of clopidogrel in patients with DM and CKD. Since both DM and CKD represent pandemic public health problems, the prevalence of which will double over the next 20 years, identifying antiplatelet agents with more favorable PK/PD profiles is of key importance.

Ticagrelor is an oral, reversible, non-competitive P2Y12 receptor inhibitor with more potent and consistent platelet inhibition than clopidogrel. In large-scale clinical investigation, ticagrelor significantly reduced ischemic events to a greater extent than clopidogrel, a finding that was consistent also among DM patients. In patients with CKD, ticagrelor led to an even greater relative risk reduction of ischemic events, including cardiovascular mortality, compared to patients without CKD. However, to date there has been no analysis on the efficacy of ticagrelor in DM patients according to CKD status. Moreover, although PD studies showed enhanced platelet inhibition associated with ticagrelor, it is unknown how this may be affected by CKD status. Ultimately, how PK/PD profiles of different ticagrelor dosing regimens may be affected by DM and CKD status is also unknown. The proposed study is aimed to show the impact of CKD status among patients with DM and CAD on PD and PK profiles of ticagrelor used at 2 doses (90mg bid and 60mg bid) in the setting of a prospective, randomized, cross-over trial.
Miglustat is an N-alkylated iminosugar, a synthetic analog of D‑glucose. The pharmacologic class is enzyme stabilizer.

The chemical name is 1,5-(butylimino)-1,5-dideoxy-D-glucitol with the molecular weight of 219.28 g/mol, the molecular formula C10H21NO4, and the following chemical structure:

Miglustat is a white to off-white crystalline solid (powder). It is highly soluble in water (>1,000 mg/mL as a free base).

OPFOLDA (miglustat) capsules each contain 65 mg of miglustat for oral administration. The inactive ingredients are: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized maize starch, and sucralose. The capsule shells include black iron oxide, gelatin, and titanium dioxide. Edible printing ink includes black iron oxide, and shellac.
PURPOSE: To investigate the incidence and patterns of chest compression-associated internal thoracic artery injury (CAI) during cardiopulmonary resuscitation and identify the embolization techniques used to treat hemorrhage.
MATERIALS AND METHODS: A retrospective study was conducted in the patients who underwent transcatheter arterial embolization (TAE) for life-threatening hemorrhage caused by CAI at two tertiary care centers between May 2013 and December 2019. Data on background characteristics, imaging findings, embolization and outcomes were collected from the medical records.
RESULTS: Among 385 patients in whom circulation returned after resuscitation, there were 9 patients (2.3%) who required TAE for CAI. Eight of 9 patients had acute myocardial infarction, and all had been started on extracorporeal membrane oxygenation before TAE. Seven patients had unilateral, and two had bilateral internal thoracic artery injuries. Main trunk injury of internal thoracic artery was seen in 27%, while branch injury in 73%. Six patients (67%) had multiple injuries in the internal thoracic artery territory, and five (56%) had injuries to other vessels. In all cases, we embolized the main trunk of the internal thoracic artery using n-butyl 2-cyanoacrylate and coils (n = 8), a gelatin sponge only (n = 2), or coils and a gelatin sponge (n = 1). TAE was technically successful in all, without any complication. The 30-day mortality rate was 44%.
CONCLUSIONS: CAI needing hemostatic intervention occurred in 2.3% of patients after successful cardiopulmonary resuscitation. Branch injury was more common than main trunk injury, and multiple vessel injuries were common. TAE appears to be safe and effective for controlling life-threatening hemorrhage.
Dyads will participate in 6 30-minute skills-based sessions. Sessions will also include provision of anticipatory guidance and and resources to manage cardiac arrest-specific stressors. A clinical psychologist will deliver all of the sessions. The main intervention goal is to provide dyads with resiliency skills and resources to reduce emotional distress and prevent chronic distress.
Wave 2 clinicians provided treatment as usual (e.g., usual care) with the children they treated during the initial two years of the project. Afterwards, they trained in MATCH and used it to treat children in their clinics with weekly case consultation from our study team of MATCH experts, supported by the TRAC system.